Journal of Lipid Research, Vol 22, 24-36, Copyright © 1981 by Lipid Research, Inc.

ARTICLES

Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man

SM Grundy, HY Mok, L Zech and M Berman

The mechanisms for the hypolipidemic action of nicotinic acid were examined in 12 patients with hyperlipidemia. Most patients were studied in the hospital on a metabolic ward. The first month was a control period followed by 1 month on nicotinic acid. During treatment with nicotinic acid, the triglycerides (TG) decreased in total plasma by an average of 52% and in very low density lipoproteins (VLDL) by 36%. Transport rates of VLDL-TG were determined by multicompartmental analysis following injection of [3H]glycerol as a precursor. Nicotinic acid decreased transport (synthesis) of VLDL-TG by an average of 21%. Kinetic modeling of the VLDL-TG data suggested that the TG reduction was due to a decrease in TG content of VLDL and hence a reduction in lipoprotein size more than number. For the whole group, plasma cholesterol fell during nicotinic acid therapy by a mean of 22%. The drug produced no detectable changes in fecal excretions of cholesterol (neutral steroids) or bile acids. However, it induced a small but significant increment in hepatic secretion of biliary cholesterol that might have led to a net loss of cholesterol from the body even though this loss could not be detected by sterol balance. Despite this increase in outputs of biliary cholesterol, there was not a significant increase in molar % cholesterol or in % saturation of gallbladder bile. Therefore, it is doubtful that nicotinic acid enhances the risk for cholesterol gallstones.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L.-H. Zhang, V. S. Kamanna, M. C. Zhang, and M. L. Kashyap Niacin inhibits surface expression of ATP synthase {beta} chain in HepG2 cells: implications for raising HDL J. Lipid Res., June 1, 2008; 49(6): 1195 - 1201. [Abstract] [Full Text] [PDF]

				S. Ardoin, C. Sandborg, and L. Schanberg Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 618 - 626. [Abstract] [PDF]

				W. L. Isley, J. M. Miles, B. W. Patterson, and W. S. Harris The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus J. Lipid Res., January 1, 2006; 47(1): 193 - 200. [Abstract] [Full Text] [PDF]

				S. H. Ganji, S. Tavintharan, D. Zhu, Y. Xing, V. S. Kamanna, and M. L. Kashyap Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells J. Lipid Res., October 1, 2004; 45(10): 1835 - 1845. [Abstract] [Full Text] [PDF]

				J. McKenney New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders Arch Intern Med, April 12, 2004; 164(7): 697 - 705. [Abstract] [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				T. Sakai, V. S. Kamanna, and M. L. Kashyap Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1783 - 1789. [Abstract] [Full Text] [PDF]

				L. M. Stead, K. P. Au, R. L. Jacobs, M. E. Brosnan, and J. T. Brosnan Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E1095 - E1100. [Abstract] [Full Text] [PDF]

				W. Wang, A. Basinger, R. A. Neese, B. Shane, S.-A Myong, M. Christiansen, and M. K. Hellerstein Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E540 - E547. [Abstract] [Full Text] [PDF]

				M. B. Elam, D. B. Hunninghake, K. B. Davis, R. Garg, C. Johnson, D. Egan, J. B. Kostis, D. S. Sheps, E. A. Brinton, and for the ADMIT Investigators Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial JAMA, September 13, 2000; 284(10): 1263 - 1270. [Abstract] [Full Text] [PDF]

				W. Wang, A. Basinger, R. A. Neese, M. Christiansen, and M. K. Hellerstein Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women Am J Physiol Endocrinol Metab, July 1, 2000; 279(1): E50 - E59. [Abstract] [Full Text] [PDF]

				M. J. Zema Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study J. Am. Coll. Cardiol., March 1, 2000; 35(3): 640 - 646. [Abstract] [Full Text] [PDF]

				R. H. Knopp Drug Treatment of Lipid Disorders N. Engl. J. Med., August 12, 1999; 341(7): 498 - 511. [Full Text] [PDF]

				F.-Y. Jin, V. S. Kamanna, and M. L. Kashyap Niacin Accelerates Intracellular ApoB Degradation by Inhibiting Triacylglycerol Synthesis in Human Hepatoblastoma (HepG2) Cells Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1051 - 1059. [Abstract] [Full Text] [PDF]

				F.-Y. Jin, V. S. Kamanna, and M. L. Kashyap Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells : Implication for Reverse Cholesterol Transport Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 2020 - 2028. [Abstract] [Full Text]

				T. K. Basu and S. Mann Vitamin B-6 Normalizes the Altered Sulfur Amino Acid Status of Rats Fed Diets Containing Pharmacological Levels of Niacin without Reducing Niacin's Hypolipidemic Effects J. Nutr., January 1, 1997; 127(1): 117 - 121. [Abstract] [Full Text]